Products for Research Use Only
RegisterLogin

Ponalrestat

CAT: 0804-HY-106697-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-106697-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM) . Ponalrestat inhibits the conversion of glucose to sorbitol[1][2][3].
CAS Number
72702-95-5
Product Name Alternative
ICI 128436
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Aldose Reductase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ponalrestat.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
OC(CC(C1=C2C=CC=C1)=NN(CC3=C(C=C(Br)C=C3)F)C2=O)=O
Molecular Formula
C17H12BrFN2O3
Molecular Weight
391.19
Precautions
H302, H315, H319, H335
References & Citations
[1]Ward WH, et al. Ponalrestat: a potent and specific inhibitor of aldose reductase. Biochem Pharmacol. 1990 Jan 15;39 (2) :337-46.|[2]Bresson E, et al. The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium. J Clin Endocrinol Metab. 2011 Jan;96 (1) :210-9.|[3]Calcutt NA, et al. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004 Apr;47 (4) :718-24.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
BUP06837-01Ponalrestat
BP300109Ponalrestat - Bio-X TM

Popular Products